USA |NASDAQ |USD |ADR
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-0.61 | $-0.74 | $-0.52 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $4.43M | $1.78M | $3.84M |
Bicycle Therapeutics's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 10 | $-0.69 | $-1.29 | $-0.28 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 10 | $-2.79 | $-3.36 | $-2.02 |
| Dec 2022 | 10 | $-3.07 | $-4.61 | $-0.71 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 1 | $-0.68 | $-0.67 | $-0.77 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 3 | $-2.75 | $-2.77 | $-2.68 |
| Dec 2022 | 1 / 2 | $-2.95 | $-2.97 | $-3.42 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 10 | $4.79M | $1.50M | $13.40M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 10 | $14.13M | $6.60M | $30.40M |
| Dec 2022 | 10 | $19.41M | $7.14M | $67.01M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-0.61 | - | - |
| Aug 5, 2021 | Jun 2021 | $-0.67 | $-0.74 | -10.78% |
| May 6, 2021 | Mar 2021 | $-0.71 | $-0.73 | -3.18% |
| Mar 11, 2021 | Dec 2020 | $-0.41 | $-0.83 | -101.60% |
| Nov 5, 2020 | Sep 2020 | $-0.53 | $-0.52 | 1.89% |
| Aug 5, 2020 | Jun 2020 | $-0.46 | $-0.67 | -45.02% |
| May 7, 2020 | Mar 2020 | $-0.38 | $-0.63 | -64.36% |
| Mar 10, 2020 | Dec 2019 | $-0.52 | $-0.25 | 51.62% |
| Nov 7, 2019 | Sep 2019 | $-0.70 | $-0.53 | 23.74% |
| Aug 8, 2019 | Jun 2019 | $-0.62 | $-0.66 | -6.45% |
| May 23, 2019 | Mar 2019 | - | $-0.49 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 11, 2021 | Dec 2020 | $-2.27 | $-2.65 | - |
| Mar 10, 2020 | Dec 2019 | $-2.70 | $-1.93 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $4.43M | - | - |
| Aug 5, 2021 | Jun 2021 | $2.31M | $1.78M | 0.77% |
| May 6, 2021 | Mar 2021 | $1.81M | $1.81M | 1.00% |
| Mar 11, 2021 | Dec 2020 | $3.99M | $3.85M | 0.96% |
| Nov 5, 2020 | Sep 2020 | $3.06M | $3.84M | 1.26% |
| Aug 5, 2020 | Jun 2020 | $2.36M | $1.57M | 0.67% |
| May 7, 2020 | Mar 2020 | $10.35M | $1.13M | 0.11% |
| Mar 10, 2020 | Dec 2019 | $1.85M | $5.28M | 2.85% |
| Nov 7, 2019 | Sep 2019 | $1.32M | $614.00K | 0.47% |
| Aug 8, 2019 | Jun 2019 | $1.03M | $1.52M | 1.48% |
| May 23, 2019 | Mar 2019 | - | $6.38M | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 11, 2021 | Dec 2020 | $10.62M | $10.39M | -2.17% |
| Mar 10, 2020 | Dec 2019 | $9.99M | $13.80M | 38.15% |
BCYC's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 10 analysts, the average EPS estimation for Bicycle Therapeutics's next quarterly earnings is $-0.61, with a low EPS estimation of $-0.79, and a high estimation of $-0.26.
Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.59, the last 2 month trend is $-0.59, and the 3 month trend is $-0.47.
Based on 8 analysts, the average revenue estimation is $4.43M, with a low revenue estimation of $1.50M, and a high estimation of $13.40M.
Bicycle Therapeutics's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.
BCYC's earnings per share (EPS) was $-0.74, missing the consensus analysts forecast of $-0.67 by -10.78%.
The EPS was lower than the previous fiscal quarter (Mar 2021) by 1.37%, and lower than the same period a year before (Jun 2020) by 10.45%.
Revenues were $1.78M, worse than the forecast of $2.31M by -22.73%, down by -1.27% from the previous quarter , and up by 13.62% from the same period last year.
The company reported a net income of $-17.91M.Free cash flow for the quarter was $-26.87M , compared to $-14.33M last quarter and $-12.65M a year before.
BCYC ended the quarter with $30.40M in total debt, a decrease of -8.52% compared to the previous quarter, and an increase of 1922.69% compared to the same quarter a year before.
Bicycle Therapeutics's previous annual earnings date was Mar 11, 2021 for its fiscal year ended Dec 31, 2020.
BCYC's earnings per share (EPS) was $-2.65, missing the consensus analysts forecast of $-2.27 by 16.74% , and lower than the previous year's EPS (Dec 2019) by 36.99%.
Revenues were $10.39M, worse than the forecast of $10.62M by -2.17%, and down by -24.72% from previous year's revenue.
The company reported a net income of $-51.01M.
Bicycle Therapeutics reported a free cash flow of $-18.99M for its fiscal year, compared to $-30.17M a year ago.
The company ended the fiscal year with $15.35M in total debt, an increase of 711.69% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
